Gliadin (a wheat gluten protein) increases intestinal permeability via zonulin, which the archive presents (by listing the studies under the white-flour rule) as relevant to everyone eating white flour.
Original statement
No Arabic original wording available.
Translation
Gliadin (a wheat gluten protein) increases intestinal permeability via zonulin, which the archive presents (by listing the studies under the white-flour rule) as relevant to everyone eating white flour.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (study selection and narrative)
- Origin
- https://eltayebat.com/rule/refined-wheat/
- Attribution uncertainty
- Written by the archive operators; the study citations are the archive's, not shown to be Elawady's own.
- Claimed mechanism
Gliadin binds CXCR3, triggers zonulin release and opens tight junctions.
- Claimed health effect
Implied 'leaky gut' and harm in the general population.
- Population concerned
Implied: everyone.
- Geographic restriction by Elawady
none found
Scientific assessment
Unclear / insufficient evidence – The data do not allow an assessment either way.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
By citation: gluten makes the gut leaky in everyone.
2. What is demonstrably correct?
Gliadin can transiently increase permeability in lab models; in coeliac disease the effect is sustained.
3. What is wrong or exaggerated?
Transferring lab observations to clinical harm in the general population is not justified. Notably, Elawady himself says the problem is 'not gluten' (video h4iNUew0djI), which conflicts with the archive's use of these studies.
4. What remains unclear?
Clinical significance of transient permeability changes in healthy people.
5. Which studies support it?
A-WHT-16, A-WHT-17, I-WHT-121 (gliadin raised permeability of biopsy explants from all groups, including controls) - all laboratory evidence.
6. Which studies contradict it?
I-WHT-122 (5 days of 16 g/day gluten did not change permeability markers in healthy people or NCGS), I-WHT-123 (commercial serum zonulin assays do not measure zonulin), I-WHT-07 (indirect context), I-GRN-01.
7. What applies to Germany and Europe?
No European body recommends gluten avoidance for people without diagnosed gluten-related disease.
8. What is known about Egypt?
Same.
9. What practical conclusion is appropriate?
No basis for general gluten avoidance; coeliac disease requires strict avoidance.
Assessment details
- Rationale for certainty of evidence
The laboratory findings are real (cell lines, mouse tissue, human biopsy explants: A-WHT-16, A-WHT-17). In non-coeliac biopsies the permeability rise was limited and transient (A-WHT-16). No study shows clinical harm from gluten in people without coeliac disease; long-term gluten intake was not associated with coronary disease (I-WHT-07), and blinded challenges in self-reported gluten sensitivity did not show gluten-specific symptoms (I-GRN-01).
- Source quality
In-vitro/ex-vivo mechanistic studies; one has a COI (Alba Therapeutics, a zonulin-antagonist developer) (A-WHT-17).
- Regional transferability
Not region-dependent.
- Individual exceptions
Coeliac disease: gluten is clearly harmful.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: Does gliadin increase intestinal permeability via zonulin in a way that is clinically relevant for everyone eating white flour?
Research question in detail (PECO)
- Population
- People without coeliac disease
- Intervention or exposure
- Gliadin/gluten
- Comparison
- No gluten / placebo
- Geographic scope
- universal biology
- Outcomes
- Intestinal permeability in vivo
- Ex vivo permeability
- Clinical outcomes
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
In the lab, gliadin made gut tissue leakier in everyone
Hollon J et al.. Nutrients 2015 · PMID 25734566 · DOI 10.3390/nu7031565 Laboratory / cell studyabstract checkednewly addedGliadin raised permeability of biopsy explants from all groups, including non-coeliac controls.
- Actual result
- Greater permeability increase with gliadin than media in all four groups.
- Methodological quality
- low (ex vivo, tiny groups)
- Relevance
- very indirect
- Limitations
- 2-hour lab exposure.
Gluten protein and gut tissue in the lab
Drago S et al.. Scand J Gastroenterol 2006 · PMID 16635908 · DOI 10.1080/00365520500235334 Laboratory / cell studyabstract checkedGliadin induced zonulin release and transient permeability increase in non-coeliac tissue.
- Actual result
- Limited, transient in non-coeliac biopsies.
- Methodological quality
- low (in vitro)
- Relevance
- very indirect
- Limitations
- Lab model.
What speaks against the claim?
Five days of gluten did not make the gut leakier in living people
Iven J et al.. United European Gastroenterol J 2025 · PMID 40138597 · DOI 10.1002/ueg2.70014 Randomised controlled trialabstract checkednewly addedIn vivo: 16 g gluten/day for 5 days did not change intestinal permeability or inflammation markers in healthy people or NCGS.
- Actual result
- No differences in biological markers.
- Methodological quality
- moderate (randomised crossover, small)
- Relevance
- direct
- Limitations
- Single-blind; short.
Common blood tests for zonulin do not actually measure zonulin
Ajamian M et al.. PLoS One 2019 · PMID 30640940 · DOI 10.1371/journal.pone.0210728 Otherabstract checkednewly addedCommercial serum zonulin assays do not measure zonulin.
- Actual result
- Detected haptoglobin/complement C3.
- Methodological quality
- moderate (analytical study)
- Relevance
- indirect (methodological)
- Limitations
- Two kits.
Gluten and heart disease in people without coeliac disease
Lebwohl B et al.. BMJ 2017 · PMID 28465308 · DOI 10.1136/bmj.j1892 Cohort studyfull text, structured risk-of-bias assessmentLong-term gluten intake not associated with coronary heart disease in people without coeliac disease.
- Actual result
- Full model HR 0.95 (0.88-1.02).
- Methodological quality
- high (large cohorts)
- Relevance
- indirect
- Limitations
- Did not measure permeability.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Gliadin can transiently raise permeability in lab models, but a human feeding trial found no in vivo effect in healthy people, and many zonulin measurements are unreliable; there is no evidence of clinical harm in people without coeliac disease.
Why some studies weigh more
In vivo human data outweigh ex vivo explant findings for the question of relevance to everyone.
Is a causal relationship established? Not established Lab effect shown; clinical relevance not shown.
Remaining uncertainty
Long-term subtle effects.
Justified conclusion
No basis for general gluten avoidance; coeliac disease requires strict avoidance.
Why do studies seem to disagree?
Ex vivo (I-WHT-121, A-WHT-16) vs in vivo (I-WHT-122): isolated gliadin on tissue for 2 hours vs whole food in living gut with mucus, digestion and repair; different questions.
Does this depend on the country?
- General biological effects
- Universal.
- Eating habits
- Not relevant.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- Not relevant.
A regional difference that changes the conclusion is not supported by robust data.
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Clinically relevant permeability increase from gluten in non-coeliac people
- Starting level
- low (observational studies)
- Reasons for downgrading
- indirectness
- imprecision
- Result
- very low
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ESsCD (European Society for the Study of Coeliac Disease): ESsCD guideline for coeliac disease and other gluten-related disorders (Al-Toma et al., UEG J 2019; study I-GRN-02) (2019) · Original publication
Diagnostic testing (serology and biopsy) should be performed on a gluten-containing diet; a gluten-free diet should be introduced only when diagnosis is conclusive (strong, high); patients with coeliac disease should adhere to a lifelong gluten-free diet (strong, high); gluten-containing cereals are wheat, barley and rye; maize and oats are naturally gluten-free but can be contaminated; uncontaminated oats are tolerated by most patients; foods labelled gluten-free must contain <=20 ppm (EC 41/2009); NCGS is considered only after coeliac disease and wheat allergy are excluded on a gluten-containing diet; patients advised to eat whole-grain rice, maize, potatoes and vegetables.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| PubMed | 26 October 2026 | zonulin[ti] AND (ELISA[tiab] OR assay[tiab] OR "may not be"[tiab] OR validity[tiab] OR properdin[tiab]) | contradicting evidence | 114 | |
| PubMed | 26 October 2026 | (Scheffler L[au] AND zonulin[ti]) OR (Ajamian M[au] AND zonulin[ti]) | contradicting evidence | 3 | |
| PubMed | 26 October 2026 | Hollon J[au] AND gliadin[ti] AND permeability[ti] | supporting evidence | 1 | |
| PubMed | 26 October 2026 | (gluten[ti] OR gliadin[ti]) AND (intestinal permeability[tiab] OR gut permeability[tiab] OR barrier[tiab]) AND (healthy[tiab]) AND (randomized[tiab] OR crossover[tiab] OR explant*[tiab] OR biopsy[tiab]) | both directions | 7 |
Open questions
Longer in vivo challenges with validated permeability tests.
How deeply was this checked?
7 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 6 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Unclear / insufficient evidence (low)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Unclear / insufficient evidence (low)
Unchanged. Honest support (I-WHT-121) and new counter-evidence (I-WHT-122, I-WHT-123) both add little certainty; the archive's extrapolation to everyone remains unsupported. A move to “Potentially false” was considered but not made because the in vivo trial is small and short.
New sources: I-WHT-121 I-WHT-122 I-WHT-123
In plain language
Two laboratory studies cited by the archive show that a wheat protein can briefly loosen the gut lining in cells and tissue samples. In people with coeliac disease this effect lasts; in others it was small and short. Studies in people have not shown that gluten harms those without coeliac disease. Dr. Diaa himself said in a video that the problem is not gluten.
Studies on this claim
Studies supporting the claim (3)
-
Gluten protein and gut tissue in the lab
Drago S et al.. Scand J Gastroenterol 2006 · PMID 16635908 · DOI 10.1080/00365520500235334Laboratory / cell studycited by the Tayebat archiveabstract checkedGliadin briefly loosened gut tissue samples; strongly in coeliac tissue, slightly in others.
Mechanistic only.
Does the study support the specific claim? Unclear · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Gliadin and permeability
- How was the study done?
Cells and biopsies
- How many people, animals or samples were studied?
Lab
- What was actually found?
Transient effect in non-coeliac
- What do the results mean in everyday life?
No direct meaning for healthy eaters
- What are the study's limitations?
Lab only
- What does it say about Elawady's specific claim?
Does not show harm
- What can explicitly not be concluded from this study?
Clinical harm
-
How gluten protein binds gut cells
Lammers KM et al.. Gastroenterology 2008 · PMID 18485912 · DOI 10.1053/j.gastro.2008.03.023Laboratory / cell studycited by the Tayebat archiveabstract checkedGliadin binds a receptor and increases permeability in mouse tissue.
Mechanistic only.
Does the study support the specific claim? Unclear · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Mechanism
- How was the study done?
Lab
- What was actually found?
CXCR3 binding
- What do the results mean in everyday life?
Lab mechanism
- What are the study's limitations?
No clinical data; COI
- What does it say about Elawady's specific claim?
Does not show harm in people
- What can explicitly not be concluded from this study?
Clinical harm
-
In the lab, gliadin made gut tissue leakier in everyone
Hollon J et al.. Nutrients 2015 · PMID 25734566 · DOI 10.3390/nu7031565Laboratory / cell studyindependent cross-checkabstract checked★ key studyBiopsy samples from coeliac patients, gluten-sensitive people and controls all became more permeable when exposed to gliadin for two hours.
Gliadin increased permeability ex vivo in all groups, including controls.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Gliadin and gut permeability.
- How was the study done?
Biopsy explants.
- How many people, animals or samples were studied?
23 donors.
- What was actually found?
Permeability rose in all groups.
- How large was the observed effect?
Not quantified in abstract.
- What do the results mean in everyday life?
Lab effect exists.
- What are the study's limitations?
Ex vivo, tiny groups.
- What does it say about Elawady's specific claim?
Supports the lab premise only.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Cannot show harm in living healthy people.
No study in this group is marked as key.
Studies contradicting or limiting the claim (4)
-
Gluten and heart disease in people without coeliac disease
Lebwohl B et al.. BMJ 2017 · PMID 28465308 · DOI 10.1136/bmj.j1892Cohort studyindependent cross-checkfull text, structured risk-of-bias assessment★ key studyEating more gluten was not linked to more heart disease over 26 years.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Gluten and CHD
- How was the study done?
Cohort
- How many people, animals or samples were studied?
110,017
- What was actually found?
No association
- How large was the observed effect?
HR 0.95
- What do the results mean in everyday life?
Gluten is not a heart risk for non-coeliacs
- What are the study's limitations?
FFQ estimate
- What does it say about Elawady's specific claim?
Contradicts general gluten harm
- Do the results apply to Germany and Europe?
Moderate
- What can explicitly not be concluded from this study?
Says nothing about gut permeability, intestinal symptoms or whether gluten sensitivity exists; only about heart disease
-
Is it gluten or another wheat component?
Skodje GI et al.. Gastroenterology 2018 · PMID 29102613 · DOI 10.1053/j.gastro.2017.10.040Randomised controlled trialindependent cross-checkabstract checked★ key studyIn people who think they react to gluten, a wheat sugar (fructan) caused more symptoms than gluten.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Gluten vs fructan
- How was the study done?
Blinded crossover RCT
- How many people, animals or samples were studied?
59
- What was actually found?
Fructan, not gluten
- How large was the observed effect?
GSRS 38.6 vs 33.1
- What do the results mean in everyday life?
Symptoms may come from wheat carbohydrates
- What are the study's limitations?
Small
- What does it say about Elawady's specific claim?
Partly supports 'not gluten'; says nothing about coeliac disease
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Coeliac disease
-
Five days of gluten did not make the gut leakier in living people
Iven J et al.. United European Gastroenterol J 2025 · PMID 40138597 · DOI 10.1002/ueg2.70014Randomised controlled trialindependent cross-checkabstract checked★ key studyIn 36 adults, eating 16 g of gluten daily for 5 days did not change gut permeability or inflammation markers compared with gluten-free food.
No in vivo change in permeability markers with 16 g/day gluten for 5 days.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test gluten effects in vivo.
- How was the study done?
Randomised crossover.
- How many people, animals or samples were studied?
36 adults.
- What was actually found?
No biomarker changes; symptoms not gluten-specific.
- How large was the observed effect?
No differences.
- What do the results mean in everyday life?
Lab permeability effects did not show up in people.
- What are the study's limitations?
Small, single-blind.
- What does it say about Elawady's specific claim?
Contradicts applying lab findings to everyone.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Cannot rule out long-term subtle effects.
-
Common blood tests for zonulin do not actually measure zonulin
Ajamian M et al.. PLoS One 2019 · PMID 30640940 · DOI 10.1371/journal.pone.0210728Otherindependent cross-checkabstract checkedAnalysis showed two widely used commercial zonulin tests detect other proteins (haptoglobin, complement C3).
Serum zonulin tests used in many studies do not measure zonulin.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Validate zonulin tests.
- How was the study done?
Laboratory protein analysis.
- How many people, animals or samples were studied?
Sera samples.
- What was actually found?
Kits detect other proteins.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Be cautious with "leaky gut" zonulin claims.
- What are the study's limitations?
Two kits.
- What does it say about Elawady's specific claim?
Weakens extrapolation of the zonulin pathway.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Does not disprove the biopsy findings.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
No European body recommends gluten avoidance for people without diagnosed gluten-related disease.
Egypt
Same.
What applies in my country?
General scientific assessment
Unclear / insufficient evidence Lab findings are real, but there is no evidence that they translate into harm for people without coeliac disease.
The following areas of food safety are relevant to this statement:
- Pesticides and pesticide residues
- Mycotoxins (mould toxins)
Cereals and rice
Choose a country to see the checked information for it.
Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.
Country of residence or purchase Compare with another country
References
- Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines.. Drago S et al.. Scand J Gastroenterol 2006 · PMID 16635908 · DOI 10.1080/00365520500235334
- Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3.. Lammers KM et al.. Gastroenterology 2008 · PMID 18485912 · DOI 10.1053/j.gastro.2008.03.023
- Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity.. Hollon J et al.. Nutrients 2015 · PMID 25734566 · DOI 10.3390/nu7031565
- Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study.. Lebwohl B et al.. BMJ 2017 · PMID 28465308 · DOI 10.1136/bmj.j1892
- Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity.. Skodje GI et al.. Gastroenterology 2018 · PMID 29102613 · DOI 10.1053/j.gastro.2017.10.040
- Impact of Acute and Sub-Acute Gluten Exposure on Gastrointestinal Symptoms and Psychological Responses in Non-Coeliac Gluten Sensitivity: A Randomised Crossover Study.. Iven J et al.. United European Gastroenterol J 2025 · PMID 40138597 · DOI 10.1002/ueg2.70014
- Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems.. Ajamian M et al.. PLoS One 2019 · PMID 30640940 · DOI 10.1371/journal.pone.0210728